Varenicline

CHEMBL1076903 Phase 4 Одобрено Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

211.3 g/mol

LogP

0.8

Phase

4

This prescription medication is used to help adults quit smoking by both reducing the pleasurable effects of cigarettes and relieving withdrawal symptoms. It works by partially stimulating and blocking nicotinic acetylcholine receptors in the brain that respond to nicotine. Some patients experience changes in mood or behavior during treatment, so any unusual thoughts or feelings should be reported to a doctor.

Молекулярная масса

211,2600 g/mol

LogP

0,80

TPSA

37,80 Å²

Правило пяти Липинского

Соответствует

Терапевтические области

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Respiratory Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Asthma Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Stroke Obesity Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Chronic Pain HIV/AIDS Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure

Embed this structure

SMILES

c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1

InChI

InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2/t8-,9+

Molecular Formula

C13H13N3

HBD / HBA

1 / 3

Вращаемые Связи

0

Тяжёлые Атомы

16

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

This prescription medication is used to help adults quit smoking by both reducing the pleasurable effects of cigarettes and relieving withdrawal symptoms. It works by partially stimulating and blocking nicotinic acetylcholine receptors in the brain that respond to nicotine. Some patients experience changes in mood or behavior during treatment, so any unusual thoughts or feelings should be reported to a doctor.

Yes, Varenicline is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1076903. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5310966. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Ищете информацию, доступную для пациентов?

Varenicline на PillFYI

Структура

Краткие Данные

Формула: C13H13N3
Синонимы: 4

Внешние ссылки

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.